A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)

Lancet

Volumn 348, Issue 9038, 1996, Pages 1329-1339

  Gent, M ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

ADULT; AGED; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STROKE;

EID: 0030590746     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)09457-3     Document Type: Article

References (14)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50 and 310-18.
2. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320-31.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
4. Hirsh J, Dalen JE, Fuster V, Harker L, Patrono C, Roth GJ. Aspirin and other platelet-active drugs: the relationship between dose, effectiveness, and side-effects. Chest. 108:(suppl):1995;S247-57.
5. Gent M. A systematic overview of randomized trials of antiplatelet agents for the prevention of stroke, myocardial infarction, and vascular death. In: Hass WK, Easton JD, eds. Ticlopidine, platelets and vascular disease. New York: Springer-Verlag, 1993: 99-116.
6. Moloney BA. An analysis of the side-effects of ticlopidine. In: Hass WK, Easton JD, eds. Ticlopidine, platelets and vascular disease. New York: Springer-Verlag, 1993; 117-39.
7. Herbert JM, Frechel D, Vallee E, et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev. 11:1993;180-198.
8. Herbert JM, Tissinier A, Defreyn G, Maffrand JP. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation following arterial injury in rabbits. Arterioscler Thromb. 13:1993;1171-1179.
9. 3H]-2-methylthio ADP to rat platelets: effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther. 269:1994;772-777.
10. Savi P, Heilmann E, Nurden P, et al. Clopidogrel: an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin Appl Thromb Hemost. 2:1996;35-42.
11. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc. 53:1958;457-481.
12. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 35:1977;1-39.
13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
14. Cox DR. Regression models and life tables. J R Statist Soc Ser B. 34:1972;187-220.